Alles auf Aktien – Die täglichen Finanzen-NewsUltimative SpaceX-Anleitung und unterschätztes Einzeltitel-Risiko

Weight-loss drug dropout warning

6:52–7:33 · 41s

New data reveal 19% of patients quit Selen Pharma’s obesity drug due to side effects, raising doubts about its competitiveness against Novo and Lilly.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.